Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.67 |
| ▸ | HTR6 | P50406 | 3/20 | 0.67 |
| ▸ | HTR2C | P28335 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | HTR1D | P28221 | 2/20 | 0.67 |
| ▸ | MPO | P05164 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | CTSK | P43235 | 1/20 | 0.67 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | AHR | P35869 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384576 | 1.00 | HTR2A (0.67) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL3996996 | 0.89 | SLC6A4 (0.63) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL4985934 | 0.87 | HTR2A (0.77) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| Indole SCHEMBL11742048 | 0.87 | HTR2A (0.53) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL4636791 | 0.87 | SLC6A4 (0.61) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL7004146 | 0.83 | HTR2A (0.71) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL7005718 | 0.83 | HTR2A (0.71) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL1999571 | 0.83 | MEN1 (0.69) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL7889427 | 0.82 | HTR2A (0.69) | HTR2AHTR6HTR2CCYP3A4HTR1D | |
| SCHEMBL7001306 | 0.82 | HTR2A (0.69) | HTR2AHTR6HTR2CCYP3A4HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9877949-B2 | Anticancer treatment methods involving analogs and derivatives of 3-(2-substituted-ethyl) indole compounds | TUSKEGEE UNIVERSITY (US) | 2018-01-30 | — | — | US | claimed |
| US-20150164860-A1 | ANTICANCER TREATMENT METHODS INVOLVING ANALOGS AND DERIVATIVES OF 3-(2-SUBSTITUTED-ETHYL) INDOLE COMPOUNDS | TUSKEGEE UNIVERSITY (US) | 2015-06-18 | — | — | US | claimed |
| EP-1420021-A1 | DNA Methyltransferase inhibitors | The Penn State Research Foundation (US) | 2004-05-19 | — | — | EP | claimed |
| JP-2003501431-A | — | — | 2003-01-14 | — | — | JP | claimed |
| EP-1181291-A2 | DNA METHYLTRANSFERASE INHIBITORS | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000075142-A2 | DNA METHYLTRANSFERASE INHIBITORS | THE PENN STATE RESEARCH FOUNDATION (US) | 2000-12-14 | — | — | WO | claimed |
| US-6106599-A | Inks | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| WO-2024145659-A1 | HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208944-A1 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | UNIV EMORY (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208944-A1 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | UNIV EMORY (US) | 2024-06-27 | — | — | US | disclosed |
| US-4012511-A | ANTIULCER AGENTS | AYERST MCKENNA & HARRISON LTD. (CA) | 1977-03-15 | — | — | US | disclosed |
| US-4003913-A | ANTIDEPRESSANTS, ANTIULCER AGENTS | AYERST MCKENNA AND HARRISON LTD. (CA) | 1977-01-18 | — | — | US | disclosed |
| US-3995052-A | Indenopyran- and indenothiopyranalkylamines III in the treatment of depression | AYERST MCKENNA AND HARRISON LTD. (CA) | 1976-11-30 | — | — | US | disclosed |
| US-3974179-A | ANTIINFLAMMATORY, ANALGESICS, BACTERICIDES, FUNGICIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-08-10 | — | — | US | disclosed |
| US-3962236-A | ANTIDEPRESSANTS, ANTI-ULCER | AYERST MCKENNA AND HARRISON LTD. (CA) | 1976-06-08 | — | — | US | disclosed |
| US-3957816-A | ANTI-FERTILITY AGENTS | SANDOZ, INC. (US) | 1976-05-18 | — | — | US | disclosed |
| US-3939178-A | ANTIINFLAMMATORY, ANALGESIC, BACTERICIDE, FUNGICIDE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | HTR2A 12/4885HTR6 8/4885HTR2C 5/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | HTR2A 3693/4885HTR6 1713/4885HTR2C 2635/4885 |
| US-20240208944-A1 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | NOX1, NOX5, NOX3 | HTR2A 1936/4885HTR6 2656/4885HTR2C 2138/4885 |
| US-20150164860-A1 | ANTICANCER TREATMENT METHODS INVOLVING ANALOGS AND DERIVATIVES OF 3-(2-SUBSTITUTED-ETHYL) INDOLE COMPOUNDS | MCL1, BAD, API5 | HTR2A 357/4885HTR6 194/4885HTR2C 247/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | HTR2A 3355/4885HTR6 4153/4885HTR2C 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.